<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01807000</url>
  </required_header>
  <id_info>
    <org_study_id>SPD555-104</org_study_id>
    <nct_id>NCT01807000</nct_id>
  </id_info>
  <brief_title>Absorption, Metabolism and Excretion (AME) of Single Dose Radiolabeled Prucalopride Succinate in Volunteers</brief_title>
  <official_title>A Phase 1 Study to Investigate the Absorption, Metabolism, and Excretion of [14C] Prucalopride Succinate Following a Single Oral Dose in Healthy Male Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Shire</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Shire</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Phase I study to evaluate the excretion of radioactivity, the metabolic profile,
      pharmacokinetics, safety and tolerability following a single oral administration of [14C]
      Prucalopride Succinate in healthy male volunteers aged 18 to 50 years (inclusive).The purpose
      of this study is to investigate how and how quickly Prucalopride Succinate or its break down
      products are excreted by analysing blood, faeces and urine samples collected during the
      study.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>March 2013</start_date>
  <completion_date type="Actual">April 2013</completion_date>
  <primary_completion_date type="Actual">April 2013</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Area Under the Plasma Concentration Versus Time Curve From Time Zero to Infinity (AUC 0→∞) of Radiolabelled Prucalopride Succinate</measure>
    <time_frame>Over 240 hours post-dose</time_frame>
    <description>AUC can be used as a measure of drug exposure. It is derived from drug concentration and time so it gives a measure how much and how long a drug stays in a body.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Maximum Plasma Concentration (Cmax) of Radiolabelled Prucalopride Succinate</measure>
    <time_frame>Over 240 hours post-dose</time_frame>
    <description>Cmax is a term that refers to the maximum (or peak) concentration that a drug achieves in the body after the drug has been administered.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Time to Maximum Plasma Concentration (Tmax) of Radiolabelled Prucalopride Succinate</measure>
    <time_frame>Over 240 hours post-dose</time_frame>
    <description>Tmax is the time after administration of a drug when the maximum plasma concentration in the body is reached.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Plasma Half-Life (T1/2) of Radiolabelled Prucalopride Succinate</measure>
    <time_frame>Over 240 hours post-dose</time_frame>
    <description>The time it takes for the blood plasma concentration of a substance to halve.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Total Body Clearance (CL/F) of Radiolabelled Prucalopride Succinate</measure>
    <time_frame>Over 240 hours post-dose</time_frame>
    <description>The rate at which a drug is removed from the body.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Volume of Distribution (Vz/F) of Radiolabelled Prucalopride Succinate</measure>
    <time_frame>Over 240 hours post-dose</time_frame>
    <description>The distribution of a medication between plasma and the rest of the body.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>AUC 0→∞ Whole Blood Total Radioactivity of Radiolabelled Prucalopride Succinate</measure>
    <time_frame>Over 240 hours post-dose</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Cmax Whole Blood Total Radioactivity of Radiolabelled Prucalopride Succinate</measure>
    <time_frame>Over 240 hours post-dose</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Tmax Whole Blood Total Radioactivity of Radiolabelled Prucalopride Succinate</measure>
    <time_frame>Over 240 hours post-dose</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Half-Life Whole Blood Total Radioactivity of Radiolabelled Prucalopride Succinate</measure>
    <time_frame>Over 240 hours post-dose</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>AUC 0→∞ Plasma Total Radioactivity of Radiolabelled Prucalopride Succinate</measure>
    <time_frame>Over 240 hours post-dose</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Cmax Plasma Total Radioactivity of Radiolabelled Prucalopride Succinate</measure>
    <time_frame>Over 240 hours post-dose</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Tmax Plasma Total Radioactivity of Radiolabelled Prucalopride Succinate</measure>
    <time_frame>Over 240 hours post-dose</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Half-Life Plasma Total Radioactivity of Radiolabelled Prucalopride Succinate</measure>
    <time_frame>Over 240 hours post-dose</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Percent Total Radioactivity Excreted in Urine of Radiolabelled Prucalopride Succinate</measure>
    <time_frame>240 hours post-dose</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Percent Total Radioactivity Excreted in Stool of Radiolabelled Prucalopride Succinate</measure>
    <time_frame>Over 240 hours post-dose</time_frame>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">6</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>Radiolabeled Prucalopride Succinate</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Radiolabeled Prucalopride Succinate</intervention_name>
    <description>A single oral dose of 2 mg radiolabeled prucalopride succinate administered on Day 1.</description>
    <arm_group_label>Radiolabeled Prucalopride Succinate</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Males aged between 18 and 50 years, inclusive

          -  Body mass index (BMI) of ≥18 and ≤30 kg/m2

          -  No more than 2 bowel movements per day or fewer than 3 bowel movement per week

          -  Provision of signed and dated, written informed consent prior to any study specific
             procedures

        Exclusion Criteria:

          -  Have participated in a [14C]-study within the last 6 months.

          -  Exposure to clinically significant radiation within 12 months prior to dose (for
             example, serial X-ray or computed tomography scans, barium meal, current employment in
             a job requiring radiation exposure monitoring).

          -  Male subjects who consume more than 21 units of alcohol per week or 3 units per day.
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>50 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Stephen Flach</last_name>
    <role>Principal Investigator</role>
    <affiliation>Covance Clinical Research Center Inc.</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Covance Global Clinical Research Unit Inc.</name>
      <address>
        <city>Madison</city>
        <state>Wisconsin</state>
        <zip>53704</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>August 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 6, 2013</study_first_submitted>
  <study_first_submitted_qc>March 6, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 8, 2013</study_first_posted>
  <results_first_submitted>August 22, 2014</results_first_submitted>
  <results_first_submitted_qc>August 22, 2014</results_first_submitted_qc>
  <results_first_posted type="Estimate">September 5, 2014</results_first_posted>
  <last_update_submitted>August 22, 2014</last_update_submitted>
  <last_update_submitted_qc>August 22, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 5, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>[14C] PRUCALOPRIDE SUCCINATE</title>
          <description>A single oral dose of 2 mg radiolabeled prucalopride succinate administered on Day 1.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>[14C] PRUCALOPRIDE SUCCINATE</title>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="6"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="35.5" spread="10.45"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age, Customized</title>
          <units>Participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>18 - 64</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>Participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>Participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>UNITED STATES</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Area Under the Plasma Concentration Versus Time Curve From Time Zero to Infinity (AUC 0→∞) of Radiolabelled Prucalopride Succinate</title>
        <description>AUC can be used as a measure of drug exposure. It is derived from drug concentration and time so it gives a measure how much and how long a drug stays in a body.</description>
        <time_frame>Over 240 hours post-dose</time_frame>
        <population>The Pharmacokinetic Analysis Set included all subjects with at least 1 pharmacokinetic parameter estimated adequately in the Pharmacokinetic Concentration Analysis Set which included all subjects who took 1 dose of investigational product, underwent plasma pharmacokinetic sampling, and had evaluable pharmacokinetic assay results.</population>
        <group_list>
          <group group_id="O1">
            <title>[14C] PRUCALOPRIDE SUCCINATE</title>
            <description>A single oral dose of 2 mg radiolabeled prucalopride succinate administered on Day 1.</description>
          </group>
        </group_list>
        <measure>
          <title>Area Under the Plasma Concentration Versus Time Curve From Time Zero to Infinity (AUC 0→∞) of Radiolabelled Prucalopride Succinate</title>
          <description>AUC can be used as a measure of drug exposure. It is derived from drug concentration and time so it gives a measure how much and how long a drug stays in a body.</description>
          <population>The Pharmacokinetic Analysis Set included all subjects with at least 1 pharmacokinetic parameter estimated adequately in the Pharmacokinetic Concentration Analysis Set which included all subjects who took 1 dose of investigational product, underwent plasma pharmacokinetic sampling, and had evaluable pharmacokinetic assay results.</population>
          <units>ng*h/ml</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="96.5" spread="9.64"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Maximum Plasma Concentration (Cmax) of Radiolabelled Prucalopride Succinate</title>
        <description>Cmax is a term that refers to the maximum (or peak) concentration that a drug achieves in the body after the drug has been administered.</description>
        <time_frame>Over 240 hours post-dose</time_frame>
        <population>Pharmacokinetic Analysis Set</population>
        <group_list>
          <group group_id="O1">
            <title>[14C] PRUCALOPRIDE SUCCINATE</title>
            <description>A single oral dose of 2 mg radiolabeled prucalopride succinate administered on Day 1.</description>
          </group>
        </group_list>
        <measure>
          <title>Maximum Plasma Concentration (Cmax) of Radiolabelled Prucalopride Succinate</title>
          <description>Cmax is a term that refers to the maximum (or peak) concentration that a drug achieves in the body after the drug has been administered.</description>
          <population>Pharmacokinetic Analysis Set</population>
          <units>ng/ml</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.79" spread="1.10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Time to Maximum Plasma Concentration (Tmax) of Radiolabelled Prucalopride Succinate</title>
        <description>Tmax is the time after administration of a drug when the maximum plasma concentration in the body is reached.</description>
        <time_frame>Over 240 hours post-dose</time_frame>
        <population>Pharmacokinetic Analysis Set</population>
        <group_list>
          <group group_id="O1">
            <title>[14C] PRUCALOPRIDE SUCCINATE</title>
            <description>A single oral dose of 2 mg radiolabeled prucalopride succinate administered on Day 1.</description>
          </group>
        </group_list>
        <measure>
          <title>Time to Maximum Plasma Concentration (Tmax) of Radiolabelled Prucalopride Succinate</title>
          <description>Tmax is the time after administration of a drug when the maximum plasma concentration in the body is reached.</description>
          <population>Pharmacokinetic Analysis Set</population>
          <units>hours</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.75" lower_limit="1.13" upper_limit="4.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Plasma Half-Life (T1/2) of Radiolabelled Prucalopride Succinate</title>
        <description>The time it takes for the blood plasma concentration of a substance to halve.</description>
        <time_frame>Over 240 hours post-dose</time_frame>
        <population>Pharmacokinetic Analysis Set</population>
        <group_list>
          <group group_id="O1">
            <title>[14C] PRUCALOPRIDE SUCCINATE</title>
            <description>A single oral dose of 2 mg radiolabeled prucalopride succinate administered on Day 1.</description>
          </group>
        </group_list>
        <measure>
          <title>Plasma Half-Life (T1/2) of Radiolabelled Prucalopride Succinate</title>
          <description>The time it takes for the blood plasma concentration of a substance to halve.</description>
          <population>Pharmacokinetic Analysis Set</population>
          <units>hours</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="20.6" spread="5.35"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Total Body Clearance (CL/F) of Radiolabelled Prucalopride Succinate</title>
        <description>The rate at which a drug is removed from the body.</description>
        <time_frame>Over 240 hours post-dose</time_frame>
        <population>Pharmacokinetic Analysis Set</population>
        <group_list>
          <group group_id="O1">
            <title>[14C] PRUCALOPRIDE SUCCINATE</title>
            <description>A single oral dose of 2 mg radiolabeled prucalopride succinate administered on Day 1.</description>
          </group>
        </group_list>
        <measure>
          <title>Total Body Clearance (CL/F) of Radiolabelled Prucalopride Succinate</title>
          <description>The rate at which a drug is removed from the body.</description>
          <population>Pharmacokinetic Analysis Set</population>
          <units>L/h</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="20.9" spread="2.07"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Volume of Distribution (Vz/F) of Radiolabelled Prucalopride Succinate</title>
        <description>The distribution of a medication between plasma and the rest of the body.</description>
        <time_frame>Over 240 hours post-dose</time_frame>
        <population>Pharmacokinetic Analysis Set</population>
        <group_list>
          <group group_id="O1">
            <title>[14C] PRUCALOPRIDE SUCCINATE</title>
            <description>A single oral dose of 2 mg radiolabeled prucalopride succinate administered on Day 1.</description>
          </group>
        </group_list>
        <measure>
          <title>Volume of Distribution (Vz/F) of Radiolabelled Prucalopride Succinate</title>
          <description>The distribution of a medication between plasma and the rest of the body.</description>
          <population>Pharmacokinetic Analysis Set</population>
          <units>Liters</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="623" spread="185"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>AUC 0→∞ Whole Blood Total Radioactivity of Radiolabelled Prucalopride Succinate</title>
        <time_frame>Over 240 hours post-dose</time_frame>
        <population>Pharmacokinetic Analysis Set</population>
        <group_list>
          <group group_id="O1">
            <title>[14C] PRUCALOPRIDE SUCCINATE</title>
            <description>A single oral dose of 2 mg radiolabeled prucalopride succinate administered on Day 1.</description>
          </group>
        </group_list>
        <measure>
          <title>AUC 0→∞ Whole Blood Total Radioactivity of Radiolabelled Prucalopride Succinate</title>
          <population>Pharmacokinetic Analysis Set</population>
          <units>ng equivalents*h/ml</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="192" spread="31.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Cmax Whole Blood Total Radioactivity of Radiolabelled Prucalopride Succinate</title>
        <time_frame>Over 240 hours post-dose</time_frame>
        <population>Pharmacokinetic Analysis Set</population>
        <group_list>
          <group group_id="O1">
            <title>[14C] PRUCALOPRIDE SUCCINATE</title>
            <description>A single oral dose of 2 mg radiolabeled prucalopride succinate administered on Day 1.</description>
          </group>
        </group_list>
        <measure>
          <title>Cmax Whole Blood Total Radioactivity of Radiolabelled Prucalopride Succinate</title>
          <population>Pharmacokinetic Analysis Set</population>
          <units>ng equivalents/ml</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.74" spread="2.34"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Tmax Whole Blood Total Radioactivity of Radiolabelled Prucalopride Succinate</title>
        <time_frame>Over 240 hours post-dose</time_frame>
        <population>Pharmacokinetic Analysis Set</population>
        <group_list>
          <group group_id="O1">
            <title>[14C] PRUCALOPRIDE SUCCINATE</title>
            <description>A single oral dose of 2 mg radiolabeled prucalopride succinate administered on Day 1.</description>
          </group>
        </group_list>
        <measure>
          <title>Tmax Whole Blood Total Radioactivity of Radiolabelled Prucalopride Succinate</title>
          <population>Pharmacokinetic Analysis Set</population>
          <units>hours</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.75" lower_limit="1.53" upper_limit="4.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Half-Life Whole Blood Total Radioactivity of Radiolabelled Prucalopride Succinate</title>
        <time_frame>Over 240 hours post-dose</time_frame>
        <population>Pharmacokinetic Analysis Set</population>
        <group_list>
          <group group_id="O1">
            <title>[14C] PRUCALOPRIDE SUCCINATE</title>
            <description>A single oral dose of 2 mg radiolabeled prucalopride succinate administered on Day 1.</description>
          </group>
        </group_list>
        <measure>
          <title>Half-Life Whole Blood Total Radioactivity of Radiolabelled Prucalopride Succinate</title>
          <population>Pharmacokinetic Analysis Set</population>
          <units>hours</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="18.0" spread="5.18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>AUC 0→∞ Plasma Total Radioactivity of Radiolabelled Prucalopride Succinate</title>
        <time_frame>Over 240 hours post-dose</time_frame>
        <population>Pharmacokinetic Analysis Set</population>
        <group_list>
          <group group_id="O1">
            <title>[14C] PRUCALOPRIDE SUCCINATE</title>
            <description>A single oral dose of 2 mg radiolabeled prucalopride succinate administered on Day 1.</description>
          </group>
        </group_list>
        <measure>
          <title>AUC 0→∞ Plasma Total Radioactivity of Radiolabelled Prucalopride Succinate</title>
          <population>Pharmacokinetic Analysis Set</population>
          <units>ng equivalents*h/ml</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="102" spread="11.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Cmax Plasma Total Radioactivity of Radiolabelled Prucalopride Succinate</title>
        <time_frame>Over 240 hours post-dose</time_frame>
        <population>Pharmacokinetic Analysis Set</population>
        <group_list>
          <group group_id="O1">
            <title>[14C] PRUCALOPRIDE SUCCINATE</title>
            <description>A single oral dose of 2 mg radiolabeled prucalopride succinate administered on Day 1.</description>
          </group>
        </group_list>
        <measure>
          <title>Cmax Plasma Total Radioactivity of Radiolabelled Prucalopride Succinate</title>
          <population>Pharmacokinetic Analysis Set</population>
          <units>ng equivalents/ml</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.14" spread="1.29"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Tmax Plasma Total Radioactivity of Radiolabelled Prucalopride Succinate</title>
        <time_frame>Over 240 hours post-dose</time_frame>
        <population>Pharmacokinetic Analysis Set</population>
        <group_list>
          <group group_id="O1">
            <title>[14C] PRUCALOPRIDE SUCCINATE</title>
            <description>A single oral dose of 2 mg radiolabeled prucalopride succinate administered on Day 1.</description>
          </group>
        </group_list>
        <measure>
          <title>Tmax Plasma Total Radioactivity of Radiolabelled Prucalopride Succinate</title>
          <population>Pharmacokinetic Analysis Set</population>
          <units>hours</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.25" lower_limit="1.13" upper_limit="4.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Half-Life Plasma Total Radioactivity of Radiolabelled Prucalopride Succinate</title>
        <time_frame>Over 240 hours post-dose</time_frame>
        <population>Pharmacokinetic Analysis Set</population>
        <group_list>
          <group group_id="O1">
            <title>[14C] PRUCALOPRIDE SUCCINATE</title>
            <description>A single oral dose of 2 mg radiolabeled prucalopride succinate administered on Day 1.</description>
          </group>
        </group_list>
        <measure>
          <title>Half-Life Plasma Total Radioactivity of Radiolabelled Prucalopride Succinate</title>
          <population>Pharmacokinetic Analysis Set</population>
          <units>hours</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="19.7" spread="5.64"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Percent Total Radioactivity Excreted in Urine of Radiolabelled Prucalopride Succinate</title>
        <time_frame>240 hours post-dose</time_frame>
        <population>Pharmacokinetic Analysis Set</population>
        <group_list>
          <group group_id="O1">
            <title>[14C] PRUCALOPRIDE SUCCINATE</title>
            <description>A single oral dose of 2 mg radiolabeled prucalopride succinate administered on Day 1.</description>
          </group>
        </group_list>
        <measure>
          <title>Percent Total Radioactivity Excreted in Urine of Radiolabelled Prucalopride Succinate</title>
          <population>Pharmacokinetic Analysis Set</population>
          <units>percentage of radioactvity</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="84.2" spread="8.88"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Percent Total Radioactivity Excreted in Stool of Radiolabelled Prucalopride Succinate</title>
        <time_frame>Over 240 hours post-dose</time_frame>
        <population>Pharmacokinetic Analysis Set</population>
        <group_list>
          <group group_id="O1">
            <title>[14C] PRUCALOPRIDE SUCCINATE</title>
            <description>A single oral dose of 2 mg radiolabeled prucalopride succinate administered on Day 1.</description>
          </group>
        </group_list>
        <measure>
          <title>Percent Total Radioactivity Excreted in Stool of Radiolabelled Prucalopride Succinate</title>
          <population>Pharmacokinetic Analysis Set</population>
          <units>percentage of radioactivity</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13.3" spread="1.73"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>[14C] PRUCALOPRIDE SUCCINATE</title>
          <description>A single oral dose of 2 mg radiolabeled prucalopride succinate administered on Day 1.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal discomfort</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" events="6" subjects_affected="3" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Presyncope</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Dermatitis allergic</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Dry skin</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Photosensitivity reaction</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>If a multicenter publication is not submitted within twelve (12) months after conclusion, abandonment or termination of the Study at all sites, or after Sponsor confirms there shall be no multicenter Study publication, the Institution and/or such Principal Investigator may publish the results from the Institution site individually.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Study Physician</name_or_title>
      <organization>Shire Development LLC</organization>
      <phone>+1 866 842 5335</phone>
    </point_of_contact>
  </clinical_results>
</clinical_study>

